In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

The management of dyslipidaemias in the secondary prevention of coronary artery disease (CAD)

ESC webinar

Add to calendar07/05/20130:00 07/05/20130:00 Europe/Paris The management of dyslipidaemias in the secondary prevention of coronary artery disease (CAD) European Society of Cardiology contact@escardio.org DD/MM/YYYY
Primary care
Prevention
Chronic Ischaemic Heart Disease (IHD)
Dyslipidemia


Watch the webinar recording

 

G. De Backer and A. Catapano

 The objective of this webinar is to review and discuss the management of dyslipidaemias for the secondary prevention of CAD in patients with established disease; which evidence-based targets should we use and what strategies are available for achieving these?  How can we close the gap between what is recommended in guidelines and what is achieved in daily practice?

The ESC webinars are designed to help you improve your daily practice!
The format includes a case based presentation, online assesssment and live discussions with the two key opinion leaders who will deliver useful tips for your daily clinical practice.

 

Guy De Backer answers your questions

Question Answer
Could you comment on strength of different statings in both LDL-lowering and HLD-increase ? Statins differ in LDL-C lowering effect; this is clearly illustrated in the figure of addendum II to the EAS/ESC guidelines on the management of dyslipidaemias ( 2011). The difference in HDL-C rising effect is marginal and has not been shown to be of clinical relevance
Could you please repeat why is not measurable LDL-C after MI? LDL-C can be measured after an AMI. If You use the Friedewald formula then You can not estimate LDL-C  if Trigycerides are elevated > 400 mg/dL. In such a situation the use of Non-HDL-cholesterol is recommended ( Total cholesterol minus HDL-Chol);
Do we have any trials, concerning rozuvastatin vs atorvastatin effect on events? No there are not
What do you think about the role of CETP inhibitors. Proveded studies didn’t led to expected results. The initial results from RCT’s are disappointing; some RCT’s are still in progress ; at this moment there is nor place for CETP in clinical practice
How often do you see statin-induced hepatitis? What treatment do you provide in this case?  Personally I have never seen a true statin-induced hepatitis; a majority of my patients show transient and slightly elevation of SGOT/PT but I have never seen an evolution towards a full hepatitis. Recommendations to monitor enzymes in patients on lipid lowering drugs are given in chapter 11 of the EAS/ESC guidelines 2011